A
part from being an acute phase reactant, plasma fibrinogen appears to play an important role in atherogenesis. High levels of fibrinogen have been investigated as an independent risk factor in the development of stroke, cerebrovascular disease (CVD) in general, and myocardial infarction.1-3 A direct relation between plasma fibrinogen level and whole-blood and plasma viscosity and cerebral blood flow has been reported.24 Whole-blood and plasma viscosity are also influenced by the concentration of substances such as total cholesterol, low density lipoprotein (LDL), lipoprotein(a) [LP(a)], or the triglycerides.2 Heparinmediated extracorporeal LDL (total cholesterol, triglycerides, fibrinogen) precipitation (HELP) produced a rapid, controlled, and safe reduction of these substances. The hemorheologic state as well as clinical symptoms were improved in patients with cardiac disease.5,6 A similar effect may be expected in CVD because lowering of fibrinogen and lipid substances is associated with reduced whole-blood and plasma viscosity and a decrease in red cell transit time (RCTT).7 The study is designed to determine whether reduction of fibrinogen and lipid factors produced improved rheolog-ical properties of blood as well as improved clinical function in CVD, including acute stroke and multiinfarct dementia (MID).
Subjects and Methods
The trial was performed with regard to inclusion and exclusion criteria in 1991 and 1992 in 144 patients admitted consecutively to the Department of Neurology, Karl-Franzens University of Graz (Austria). Be Hachinski scale.10 All the patients were subjected to two HELP sessions within 8 days.
Thirty patients aged 67.3+8.3 years (17 men and 13 women; 16 patients with acute stroke, 14 with MID) from the remaining cohort of 52 patients in the group with acute stroke and 44 patients with MID who were not chosen by the computer to be part of the HELP group served as controls. They were even stratified according to a 1:2 ratio (one control patient for acute stroke was dropped out). These patients were connected to the HELP system, but their blood was returned via bypass by exclusion of the filtration procedure. The patients were not aware of this. Double blinding was not practical.
All the patients (HELP group and controls) received standard medical care. Besides cardiac and hypertensive drugs, pentoxiphylline, 900 mg AV in thrombembolic stroke and 1200 mg orally in MID, was administered because there have been observations that pentoxiphylline might prevent deterioration." Informed consent was received from each patient.
HELP System
The HELP system (Braun Melsungen Inc, Germany) is designed for the extracorporeal elimination of fibrinogen, total cholesterol, LDL, LP(a), and triglycerides. Blood taken from a cubital vein passes through a filter where all cellular compounds are separated from the plasma. This procedure requires a flow of between 60 and 80 mL/min. Then, isovolemic acetate-buffer solu- tion and heparin (100 U/mL) is added to the plasma to achieve pH 5.12. Under these conditions fibrinogen, cholesterol, LDL, LP(a), and triglycerides precipitate while forming molecular nets and are then eliminated by a 0.4-,um polycarbon filter. Excessive heparin is absorbed in an anion-exchange filter, and the pH is brought back to normal by bicarbonate dialysis. Plasma and blood cells are reinfused via the other cubital vein. During one HELP session 2500 to 3000 mL plasma is filtered in between 2 and 3 hours (Fig 1 and 2 ).
Laboratory Investigations
The following laboratory investigations were carried out before and after each HELP session: plasma fibrinogen (normal range, 150 to 400 mg/dL), plasma viscosity (normal range, <1.4 mPa/s), whole-blood viscosity at low shear (11 
Results

Laboratory Data
No statistically significant difference was found in fibrinogen, whole-blood and plasma viscosity, RCTT, total cholesterol, LDL, and triglycerides level in pretreatment values of the acute stroke group compared with the MID group. The two groups were therefore combined.
After two HELP sessions it was possible to reduce the measures relevant to hemorheology to between 15.7% and 53.9%. The reduction of these substances was statistically significant after each HELP session (Tables   3 and 4) . Within the controls no significant changes were found.
As expected, at day 11 (3 days after the second HELP treatment) an increase of the cited laboratory data occurred which was not statistically significant (except whole-blood viscosity at low shear rate: 8.76-+1.12 mPa/s, P<.05). (Table 5 ).
Clinical
Discussion
The aim of the experimental study was to explore whether in patients with CVD, as in coronary heart disease,56 a HELP treatment is able to change clinical symptoms due to an alteration of the hemorheologic profile. Only whole-blood viscosity at low shear rate showed a significant difference between the group with acute thrombembolic stroke and those with MID.
Hence, both groups were lumped together. To evaluate how long the HELP effect on clinical symptoms lasts, both groups will be observed separately in a follow-up.
Elevated fibrinogen may play a role in CVD, as has been confirmed by cross-sectional and longitudinal studies.,2,15.'6 Because high levels of fibrinogen, lipoproteins, or both can limit perfusion to the brain by their effects on blood rheology,'-3 which might reduce cerebral blood flow, it was of interest to examine the relation between plasma fibrinogen and serum lipoprotein levels, whole-blood and plasma viscosity, and RCTT.
In contrast to other selective procedures for extracorporeal LDL elimination, HELP also reduced fibrinogen, total cholesterol, LDL, LP(a), and triglycerides safely and effectively at the same time.67
Numerous investigations confirm our observation that an increase of all factors relevant to rheology occurs after HELP. In this study the pre-HELP values were reached within about 8 to 14 days. It is of interest that on the one hand no rebound phenomenon was detectable, and as observed in other studies, on the other hand a new "steady state" could be obtained after 4 to 8 treatments; the interval values between two treatments (value after HELP and before HELP divided by two) showed a lowering of fibrinogen and LDL of around 50%. 5, 6 Prior reports of HELP procedure showed no major complications after approximately 10 000 long-term treatments in 155 patients suffering from hyperlipidemia.56 Our own experience confirms this: during 850 HELP applications in 145 patients, no side effects have been detected that have led to interruption of the treatment.
The facts above offer an explanation for the clinical improvement after HELP, which can be interpreted by the impact on microcirculation,1516 thus providing a potential recovery of brain function.
From this point of view the vicious cycle consisting of reduced blood flow, aggregation of red blood cells and, finally, complete stasis may be interrupted by the fibrinogen-and lipoprotein-lowering power of HELP, the main effect of which is a markedly improved microcirculation. This consideration might be supported by the However, in this connection even the negative correlation of lowered fibrinogen to the partial oxygen pressure could be of interest. Thus, the improved transcutaneous partial oxygen pressure, which has already been measured in lower limbs after HELP,17 might not only be a sort of luxury perfusion of the skin vessels, but it can also be interpreted as an indicator for the increased offer of oxygen to other regions of the body, even the brain.
It is speculative indeed, but cannot be rejected entirely, that the augmented oxygen delivery to brain cells per unit of time might be one of the most important benefits of a treatment by HELP, leading to an improvement of those damaged cells that have potential for recovery.
In conclusion, HELP seems to have a considerable potential in situations where a quick and drastic fluidification of the blood is required. The apheresis causes an immediate and significant improvement of the hemorheologic pattern, obviously followed by an improvement of clinical symptoms, which has so far not been achieved by any hemorheologically active substance to a comparable degree and time.
